Skip to main content


Table 2 Main features of patients with chronic inflammatory rheumatic diseases (CIRDs) (n=22)

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

Male/Female (n) 7/15
Age (years; median/range) 53/36-79
Diagnosis: PsA/RA/AS 11/8/3
Symptoms onset (months ago; median/range) 75/24-420
CRP (mg/dl; median/25th-75th percentile) 0.09/0-1.225
ESR (mm/h; median/25th-75th percentile) 18.5/13.25-33.75
HAQ (0-3; mean/SD) 1.275 ± 0.82
DAS28-ESR (mean/SD)* 4.6 ± 1
DAS28-CRP (mean/SD)* 4.05 ± 0.99
Physician’s global assessment of disease activity (0-100 mm, VAS; mean/SD)* 56.3 ± 28.2
Patient’s global assessment of disease activity
(0-100 mm, VAS; mean/SD)*
59.6 ± 30.5
BASDAI (1-10; mean/SD)** 7.1 ± 3
Concomitant DMARDs (n/%) 10/45.4
Concomitant DMARDs and glucocorticoids (n/%) 4/18.2
Concomitant glucocorticoids (n/%) 10/45.4
No concomitant treatment (n/%) 6/27.3
  1. PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosing spondylitis; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; SD: standard deviation; DAS28: 28-joint Disease Activity Score; VAS: visual analog scale; BASDAI: Bath Ankylosing Spondylitis Diseease Activity Index; DMARDs: disease modifying anti-rheumatic drugs.
  2. *For patients with RA and PsA.
  3. **For patients with AS.